Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PARG | Q86W56 | 2/20 | 0.47 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217921 | 0.88 | DPP4 (0.54) | DPP4OPRM1OPRK1KMT2ANOX4 | |
| SCHEMBL21253391 | 0.87 | DPP4 (0.47) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL16845919 | 0.87 | KMT2A (0.51) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL8216924 | 0.86 | DPP4 (0.64) | DPP4OPRM1OPRK1KMT2ANOX4 | |
| SCHEMBL28406812 | 0.85 | DPP4 (0.58) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL17036598 | 0.85 | DPP4 (0.58) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL8417573 | 0.84 | DPP4 (0.57) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL10065404 | 0.84 | CYP3A4 (0.60) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL16845920 | 0.84 | DPP4 (0.54) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL305972 | 0.84 | DPP4 (0.59) | DPP4OPRM1OPRK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057685-A | Preparation method of alogliptin benzoate with high yield | 西安新通药物研究有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-109810094-B | Preparation method of alogliptin | 深圳市第二人民医院 | 2021-11-12 | — | — | CN | claimed |
| CN-113307777-A | Alogliptin benzoate intermediate and preparation method of Alogliptin benzoate | 石药集团欧意药业有限公司 | 2021-08-27 | — | — | CN | claimed |
| CN-112759576-A | Novel preparation process of alogliptin benzoate | 山东永丞制药有限公司 | 2021-05-07 | — | — | CN | claimed |
| CN-112341432-A | Synthesis process of alogliptin benzoate | 重庆化工职业学院 | 2021-02-09 | — | — | CN | claimed |
| CN-112250664-A | Preparation method of alogliptin benzoate | 辰欣药业股份有限公司 | 2021-01-22 | — | — | CN | claimed |
| CN-111110684-A | Compositions containing a mixture of pyrimidinedione derivatives and uses thereof | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-110642833-A | Dynamic resolution method of R-configuration alogliptin and preparation method of high-purity R-configuration alogliptin | 株洲千金药业股份有限公司 | 2020-01-03 | — | — | CN | claimed |
| EP-3292112-B1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | INDOCO REMEDIES LTD (IN) | 2019-08-14 | — | — | EP | claimed |
| US-20190023683-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | INDOCO REMEDIES LIMITED (IN) | 2019-01-24 | — | — | US | claimed |
| CN-103819450-B | A kind of new preparation process of SYR-322 | 浙江永宁药业股份有限公司 | 2016-08-24 | — | — | CN | claimed |
| CN-104151291-B | A kind of preparation method of SYR-322 polymorph crystals | JIANGSU DEYUAN PHARMACEUTICAL CO., LTD. (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-103980249-B | A kind of process for purification of SYR-322 | XINXING MEDICAMENT DEVELOPMENT CO., LTD., ANHUI PROV. (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-104672210-A | Preparation method of alogliptin and alogliptin benzoate | UNIV PEKING FOUNDER GROUP CO | 2015-06-03 | — | — | CN | claimed |
| US-8188275-B2 | hydrolase enzyme inhibors such as 2-(6-Chloro-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-29 | — | — | US | claimed |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | claimed |
| CN-1926128-A | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO INC (JP) | 2007-03-07 | — | — | CN | claimed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | claimed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023683-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | DPP4, SLC5A1, SLC5A2 | DPP4 1/4885OPRM1 3272/4885OPRK1 2298/4885 |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.